Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.

NCT00789685 is registered in ClinicalTrials.gov with Faron Pharmaceuticals Ltd as lead sponsor.

NCT NCT00789685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00789685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.
Lead sponsor
Faron Pharmaceuticals Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2009
Completion date
September 30, 2011
Enrollment
37 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury, acute respiratory distress syndrome